These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26713633)

  • 1. Immunotherapy of melanoma: efficacy and mode of action.
    Wieder T; Brenner E; Braumüller H; Röcken M
    J Dtsch Dermatol Ges; 2016 Jan; 14(1):28-37. PubMed ID: 26713633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of patients with metastatic melanoma.
    Yu Z; Si L
    Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Systemic Management of Advanced Melanoma in 2016.
    Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
    Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic use of anti-CTLA-4 antibodies.
    Blank CU; Enk A
    Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for melanoma.
    Cuevas LM; Daud AI
    Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetic and immunotherapeutic targets in metastatic melanoma.
    Melis C; Rogiers A; Bechter O; van den Oord JJ
    Virchows Arch; 2017 Aug; 471(2):281-293. PubMed ID: 28357489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Editorial].
    Schilling B; Schadendorf D
    J Dtsch Dermatol Ges; 2016 Jan; 14(1):1-2. PubMed ID: 26713629
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?
    Dempke WC; Sellmann L; Fenchel K; Edvardsen K
    Anticancer Res; 2015 Nov; 35(11):5745-57. PubMed ID: 26503995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Targeted therapies for melanoma].
    Leiter U; Meier F; Garbe C
    Hautarzt; 2014 Jul; 65(7):600-6. PubMed ID: 24962553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.
    Lau PK; Ascierto PA; McArthur G
    Curr Opin Immunol; 2016 Apr; 39():30-8. PubMed ID: 26765776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapies and melanoma].
    Routier É; Robert C; Mateus C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune-checkpoints: the new anti-cancer immunotherapies].
    Ileana E; Champiat S; Soria JC
    Bull Cancer; 2013 Jun; 100(6):601-10. PubMed ID: 23735730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.
    Shah DJ; Dronca RS
    Mayo Clin Proc; 2014 Apr; 89(4):504-19. PubMed ID: 24684873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.